Reverse Medical Corporation has announced the initial clinical use of their UNO neurovascular embolisation system for intracranial use. The device has been granted European Union CE mark approval to obstruct blood flow in the neurovasculature.
Codman Neuro announced that the US Food and Drug Administration (FDA) has classified the recently initiated medical device correction notice related to the Trufill n-BCA liquid embolic system as a Class I recall.
New stroke therapy, using a combination of non-invasive navigated transcranial stimulation along with occupational therapy, has been found to produce significant gains in motor function post-stroke, with an average of 50% of stroke survivors recovering full use of their arm.
Ornim Medical has announced that new study results demonstrate the feasibility of the Cerox cerebral oxidation monitor for measuring regional cerebral tissue oxygenation in patients with severe traumatic brain injury.
InspireMD has announced that its new CGuard carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014.
Nevro Corp has announced that the 24-month results of a prospective European clinical study using Nevro’s Senza system delivering HF10 therapy were published in the journal Pain Medicine. The study was conducted in the UK and Belgium with 65 of the 72 implanted patients (90%) being available for data collection at two years.
Success rates soared to 75% for patients who waited less than two years for a spinal cord stimulator implant, compared with 15% for patients whose who received implants 20 years after the onset of pain, according to a retrospective analysis. The length of time patients waited for a referral also varied by specialty, as shown in a scientific poster presented at the 30th Annual Meeting of the American Academy of Pain Medicine.
Lpath, according to a company release, has brought scientists one step closer to finding a potential treatment for traumatic brain injury with a recent publication showing that Lpathomab, an anti-lysophosphatidic acid antibody, reverses much of the damage caused by trauma to the nervous system.
One of the most devastating symptoms of stroke is motor deficit. It is widely believed that if there is no improvement after one year of intensive physiotherapy, the symptoms will persist for life. Now, new therapies are being developed to directly stimulate the damaged brain after a stroke in order to promote additional healing beyond that achieved by conventional physiotherapy.
A direct aspiration first pass technique (ADAPT) with a large bore aspiration catheter has been shown to be “fast, safe, simple and effective method” for acute ischaemic stroke thrombectomy. The results were published in the Journal of of NeuroInterventional Surgery.
In a study conducted by William Mehan et al, it was found that for patients with unruptured intracranial aneurysms, multilobulated morphology and interval growth of the unruptured aneurysms are “characteristics predictive of a higher risk of subsequent rupture during conservative CT angiography (CTA) follow-up.”
Avanir Pharmaceuticals announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury conducted in collaboration with the Department of Veterans Affairs and Evidera. The study will be presented at the Tenth World Congress on Brain Injury in San Francisco, USA, on Friday 21 March 2014.
A new paper published by a joint US and Canadian team in PLOS One suggests SPECT (single photon emission computed tomography)—a functional brain imaging modality that produces images of blood flow to the brain, showing areas of over or under-activity—is useful in both identifying and guiding treatment for those with traumatic brain injuries.
InspireMD announced that it has successfully enrolled the first patient in the CARENET (Carotid embolic protection study using MicroNet) multicentre European clinical trial for the new CGuard carotid embolic protection system.
A study reported in the International Headache Society’s official journal Cephalalgia found that the use of electroCore’s non-invasive vagus nerve stimulation therapy may be an effective and well tolerated treatment for migraine in certain patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos